Shikonin inhibits Vascular Smooth Muscle Cell Phenotypic Modulation and attenuates Neointimal Hyperplasia.

IF 2.4 Q3 PHARMACOLOGY & PHARMACY
Drug Research Pub Date : 2026-09-15 DOI:10.1055/a-2945-2736
Ankan Sarkar, Sakeel Ahmed, Monika Singh, Shyam Sunder Sharma, Kanwaljit Chopra, Manish Jain
{"title":"Shikonin inhibits Vascular Smooth Muscle Cell Phenotypic Modulation and attenuates Neointimal Hyperplasia.","authors":"Ankan Sarkar, Sakeel Ahmed, Monika Singh, Shyam Sunder Sharma, Kanwaljit Chopra, Manish Jain","doi":"10.1055/a-2945-2736","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Enhanced glycolytic activity drives vascular smooth muscle cell proliferation and migration. Pyruvate kinase M2, a key glycolytic enzyme, modulates cancer cell proliferation. Shikonin, an inhibitor of pyruvate kinase M2, exerts anti-proliferative effects on cancer cells; still, its involvement in vascular smooth muscle cell proliferation and neointimal hyperplasia is not established. We investigated the effects of shikonin on platelet-derived growth factor-BB-induced changes in vascular smooth muscle cell function and neointimal hyperplasia. Methods: Murine aortic vascular smooth muscle cells were pretreated with shikonin and stimulated with platelet-derived growth factor-BB. Wire injury of the carotid artery was performed in C57Bl/J6 mice to induce neointimal hyperplasia. Results: Our study observes a marked upregulation of pyruvate kinase M2 in platelet-derived growth factor-BB stimulated vascular smooth muscle cells. Shikonin inhibited pyruvate kinase M2 expression and effectively reduced platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration and also favoured the contractile vascular smooth muscle cell phenotype. Expression of matrix metalloproteinase-2 and interleukin-6 messenger RNAs was significantly lower in shikonin-treated vascular smooth muscle cells as compared to platelet-derived growth factor-BB-treated control. Pyruvate kinase M2 translocated to the mitochondria and pyruvate kinase M2 inhibition via shikonin promoted mitochondrial reactive oxygen species levels, increased oxidative stress and induced vascular smooth muscle cell apoptosis. Perivascular application of shikonin suppressed neointimal hyperplasia. Conclusion: Our findings indicate that shikonin suppresses vascular smooth muscle cell proliferation and migration, thereby limiting neointimal hyperplasia and potentially serving as a novel therapeutic strategy for atherosclerosis and restenosis.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2945-2736","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Enhanced glycolytic activity drives vascular smooth muscle cell proliferation and migration. Pyruvate kinase M2, a key glycolytic enzyme, modulates cancer cell proliferation. Shikonin, an inhibitor of pyruvate kinase M2, exerts anti-proliferative effects on cancer cells; still, its involvement in vascular smooth muscle cell proliferation and neointimal hyperplasia is not established. We investigated the effects of shikonin on platelet-derived growth factor-BB-induced changes in vascular smooth muscle cell function and neointimal hyperplasia. Methods: Murine aortic vascular smooth muscle cells were pretreated with shikonin and stimulated with platelet-derived growth factor-BB. Wire injury of the carotid artery was performed in C57Bl/J6 mice to induce neointimal hyperplasia. Results: Our study observes a marked upregulation of pyruvate kinase M2 in platelet-derived growth factor-BB stimulated vascular smooth muscle cells. Shikonin inhibited pyruvate kinase M2 expression and effectively reduced platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration and also favoured the contractile vascular smooth muscle cell phenotype. Expression of matrix metalloproteinase-2 and interleukin-6 messenger RNAs was significantly lower in shikonin-treated vascular smooth muscle cells as compared to platelet-derived growth factor-BB-treated control. Pyruvate kinase M2 translocated to the mitochondria and pyruvate kinase M2 inhibition via shikonin promoted mitochondrial reactive oxygen species levels, increased oxidative stress and induced vascular smooth muscle cell apoptosis. Perivascular application of shikonin suppressed neointimal hyperplasia. Conclusion: Our findings indicate that shikonin suppresses vascular smooth muscle cell proliferation and migration, thereby limiting neointimal hyperplasia and potentially serving as a novel therapeutic strategy for atherosclerosis and restenosis.

紫草素抑制血管平滑肌细胞表型调节并减轻新生内膜增生。
目的:糖酵解活性增强促进血管平滑肌细胞增殖和迁移。丙酮酸激酶M2是调节癌细胞增殖的关键糖酵解酶。紫草素是丙酮酸激酶M2的抑制剂,对癌细胞具有抗增殖作用;然而,其与血管平滑肌细胞增殖和新生内膜增生的关系尚不明确。我们研究了紫草素对血小板源性生长因子bb诱导的血管平滑肌细胞功能改变和新生内膜增生的影响。方法:用紫草素预处理小鼠主动脉血管平滑肌细胞,用血小板源性生长因子bb刺激。用钢丝损伤C57Bl/J6小鼠颈动脉,诱导新生内膜增生。结果:我们的研究观察到血小板衍生生长因子- bb刺激血管平滑肌细胞中丙酮酸激酶M2的显著上调。紫草素抑制丙酮酸激酶M2的表达,有效降低血小板源性生长因子bb诱导的血管平滑肌细胞的增殖和迁移,有利于血管平滑肌细胞的收缩表型。基质金属蛋白酶-2和白细胞介素-6信使rna的表达在紫草素处理的血管平滑肌细胞中显著低于血小板衍生生长因子- bb处理的对照组。丙酮酸激酶M2易位至线粒体,紫草素抑制丙酮酸激酶M2可提高线粒体活性氧水平,增加氧化应激,诱导血管平滑肌细胞凋亡。紫草素在血管周围应用抑制新生内膜增生。结论:我们的研究结果表明,紫草素可以抑制血管平滑肌细胞的增殖和迁移,从而限制内膜增生,并可能作为一种新的治疗动脉粥样硬化和再狭窄的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Research
Drug Research PHARMACOLOGY & PHARMACY-
CiteScore
3.50
自引率
0.00%
发文量
67
期刊介绍: Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书